For research use only. Not for therapeutic Use.
Adebrelimab（Cat No.:I042184）is an investigational monoclonal antibody that targets the immune checkpoint receptor PD-1 (programmed cell death protein 1), which is found on T-cells. PD-1 plays a crucial role in suppressing immune responses, allowing tumors to evade detection. By inhibiting PD-1, adebrelimab aims to restore T-cell activity, enhancing the immune system’s ability to recognize and attack cancer cells. It is being studied in clinical trials for its potential to treat various cancers, including solid tumors, with the goal of improving patient outcomes through immune system modulation.
| Catalog Number | I042184 |
| CAS Number | 2247114-85-6 |
| Purity | ≥95% |
